RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The goal of Phase I of this clinical research study is to find the highest tolerable dose of
RAD001 (everolimus) when given in combination with the standard chemotherapy regimens to
patients with ALL.
The goal of Phase II of this study is to learn if the drug combinations can help to control
ALL. The safety of these drug combinations will be also studied in both phases.